Enterprise Value to EBITDA Ratio: Xenetic Bio (XBIO)

Xenetic Biosciences Inc. (XBIO) - corporate logo

The EV/EBITDA price trajectory for Xenetic Biosciences (XBIO) is currently at 0.00. The business minimizes infrastructure costs by outsourcing drug production and testing to third-party contractors. The firm is developing unique enzyme systems to combat tumors, which are currently in the laboratory testing phase. However, the company's stability is limited by payments from Takeda and a potential need for new investments should share prices decline.

XBIO Xenetic Biosciences, Inc.: Business Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/16/2026

Xenetic Biosciences, Inc. - analytical breakdowns and key metrics (XBIO)

- current price and projected stock value:
- company stock exchange capitalization indicators:
Initial company analysis:XBIO (Xenetic Biosciences Inc.)
Manufactured products of xeneticbio.com

Inelastic demand for the XCART platform's personalized therapies provides Xenetic Biosciences (XBIO) with significant market pricing power. Analyzing the company's EV/EBITDA multiple within a historical context allows for an assessment of the total enterprise value relative to its operating profit before depreciation and amortization. This ratio measures debt load and capital efficiency, enabling investors to promptly track the balance of supply and demand for the issuer's assets.

Competitor analysis for Xenetic Biosciences

BeiGene Oncology - Enterprise Value to EBITDA Ratio|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology Corp (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen - Business Value to Operating Income Before Depreciation|BCAX (Bicara Therapeutics Inc) - EV/EBITDA Multiple|Company Value to EBITDA personalis.com PSNL|EV/EBITDA Multiple ERAS|Delcath Systems - Enterprise Value to Operating Income Before Depreciation|Y-mAbs Therapeutics Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Aura Corp AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Accuray (ARAY) - Enterprise Value to EBITDA Ratio|SLS: EV/EBITDA Multiple|Actuate Therapeutics (ACTU) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CTOR|HURA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protara Therapeutics (TARA)|Enterprise Value to Operating Income Before Depreciation Ratio FATE|EV/EBITDA Multiple WHWK (aadibio.com)|Enterprise Value to Operating Income Before Depreciation Ratio TCRX (TScan)|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation XBIT (XBiotech Inc)|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio OSTX (OS Therapies Incorporated)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics Ltd|Company Value to EBITDA Artiva Biotherapeutics ARTV|EV/EBITDA Multiple ANL|VERU - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Company Value to EBITDA|RENB: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Curis, Inc. (CRIS)|EV/EBITDA Multiple APLM|Enterprise Value to Operating Income Before Depreciation Ratio THAR|EV/EBITDA Multiple ADVB (advanbiomed.com)|GNPX - Enterprise Value to EBITDA Ratio|CLDI: Enterprise Value to EBITDA Ratio|SBFM - EV/EBITDA Multiple|SLRX (Salarius Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Ratio Purple Biotech Ltd.|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio BeOne Medicines (BGNE)|EV/EBITDA Multiple CKPT|ELEV - Company Value to EBITDA|iCAD Inc. - Enterprise Value to EBITDA Ratio|IKNA: Enterprise Value to Operating Income Before Depreciation|Notable Labs Ltd - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VIRX (Viracta Therapeutics Inc.)|MorphoSys AG (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio NAYA Biosciences|AAPGV (ascentage.com) - EV/EBITDA Multiple